World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
67784
World Ranking
3692
National Ranking
367

Overview

Kevin J. Harrington is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research primarily resides within the field of Medicine, with a strong focus on Oncology, Otorhinolaryngology, Immunology, Pulmonary and Respiratory Medicine, and Surgery.

The scientist has contributed extensively to topics such as Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Virus-based Gene Therapy Research, CAR-T Cell Therapy Research, Immunotherapy and Immune Responses, Lung Cancer Treatments and Mutations, and Cancer Research and Treatments.

Frequent co-authors working alongside Kevin J. Harrington include:

  • Alan Melcher
  • Lisa Licitra
  • Makoto Tahara
  • Pablo Nenclares
  • Robert I. Haddad

Kevin J. Harrington has published often in several scientific journals. Notable venues with multiple publications include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Radiotherapy and Oncology

Selected recent papers authored or co-authored by Harrington include:

  • "Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study," 2022, Journal of Clinical Oncology
  • "Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial," 2021, The Lancet Oncology
  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death," 2020, Journal for ImmunoTherapy of Cancer
  • "Inflammatory microenvironment remodelling by tumour cells after radiotherapy," 2020, Nature reviews. Cancer
  • "Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement," 2020, International Journal of Radiation Oncology*Biology*Physics

Best Publications

  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence

    Holly E. Barker;James T. E. Paget;Aadil A. Khan;Kevin J. Harrington

  • Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

    Christopher M Nutting;Christopher M Nutting;James P Morden;Kevin J Harrington;Kevin J Harrington;Teresa Guerrero Urbano

  • Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells.

    Cedric Gaggioli;Steven Hooper;Cristina Hidalgo-Carcedo;Robert Grosse

  • Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    Ezra E W Cohen;Denis Soulières;Christophe Le Tourneau;Christophe Le Tourneau;Christophe Le Tourneau;José Dinis

  • Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts

    Fernando Calvo;Nil Ege;Araceli Grande-Garcia;Steven Hooper

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

    H Mehanna;M Robinson;A Hartley;A Kong

  • Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

    Martin McLaughlin;Emmanuel C. Patin;Malin Pedersen;Anna Wilkins

  • Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

    Kevin J. Harrington;Kevin J. Harrington;Sima Mohammadtaghi;Paul S. Uster;Daphne Glass

  • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis

  • A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor

    Jennifer C.C. Hu;Robert S. Coffin;Ceri J. Davis;Nicola J. Graham

  • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

    Ezra E.W. Cohen;R. Bryan Bell;Carlo B. Bifulco;Barbara Burtness

  • Optimizing oncolytic virotherapy in cancer treatment.

    Kevin Harrington;Daniel J. Freeman;Beth Kelly;James Harper

  • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

    Kevin J Harrington;Robert L Ferris;George Blumenschein;A Dimitrios Colevas

  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

    Nancy Y Lee;Robert L Ferris;Amanda Psyrri;Robert I Haddad

Frequent Co-Authors

Christopher M. Nutting
Christopher M. Nutting Royal Marsden NHS Foundation Trust
Alan Melcher
Alan Melcher Institute of Cancer Research
Richard G. Vile
Richard G. Vile Mayo Clinic
Peter Selby
Peter Selby University of Leeds
Matthew C. Coffey
Matthew C. Coffey Oncolytics Biotech (Canada)
Lisa Licitra
Lisa Licitra University of Milan
Timothy Kottke
Timothy Kottke Mayo Clinic
Robert I. Haddad
Robert I. Haddad Harvard University
Robert L. Ferris
Robert L. Ferris University of Pittsburgh
Ezra E.W. Cohen
Ezra E.W. Cohen University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean attending medical school. There are a variety of related online degrees and flexible career pathways in the healthcare sector, many of which can be pursued remotely and allow diverse entry points into the industry.

For example, him programs (Health Information Management) blend technology and healthcare, opening doors to administrative and data-driven roles. If you’re looking for a specialized but quick-to-enter field, exploring medical billing and coding cost can help you find affordable programs designed for certification in just months.

Those interested in patient care at an advanced level might consider nurse practitioner programs. These allow experienced nurses to step into primary or specialized care roles with greater autonomy. Entry-level nursing, on the other hand, is accessible through various nursing school online options which offer flexible, accredited training for LPNs, RNs, and more.

With a growing demand for healthcare professionals, these online pathways offer practical, cost-effective routes into rewarding, high-impact careers.

Best Scientists Citing Kevin J. Harrington

Trending Scientists

Recently Published Articles